A Phase 3 interventional study of Fluticasone propionate and Flonase® in Seasonal Allergic Rhinitis, sponsored by Teva Pharmaceuticals USA. Terminated at 1 site in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-06-08.
Sponsored by Teva Pharmaceuticals USA (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing fluticasone in Rhinitis, Allergic, Seasonal — none open to participants now, none under way, none of them phase 3. Fluticasone · Rhinitis, Allergic, Seasonal.
Among the 28 studies testing fluticasone in Rhinitis, Allergic, Seasonal, this one is the 3rd largest by enrollment, is one of 2 that started in 2014, is one of 14 in phase 3, and was the 25th registered.
404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.
Browse Rhinitis, Allergic, Seasonal studies →None of the 28 studies testing fluticasone in Rhinitis, Allergic, Seasonal is open now. The open studies under Rhinitis, Allergic, Seasonal, anywhere →
Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,474 is above the median of 131 across 366 interventional studies indexed under Rhinitis, Allergic, Seasonal.
Median enrollment 326 across the 28 interventional studies. Of the 27 that completed or were terminated, 13 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 28 have an industry lead sponsor. The 10 most frequent:
This study is registered under Teva Pharmaceuticals USA, one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Teva Pharmaceuticals USA is the lead sponsor of 176 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Teva Pharmaceutical Industries, Ltd. has 8 studies filed under Rhinitis, Allergic, Seasonal — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing fluticasone in Rhinitis, Allergic, Seasonal, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This double-blind, randomized, placebo-controlled, parallel group, multi-site study has been designed to compare the safety and efficacy of a generic Fluticasone propionate Nasal Spray, 50 mcg (Teva Pharmaceuticals USA) to the FDA Reference Listed Drug, Flonase® (fluticasone propionate) 50 mcg nasal spray (GlaxoSmithKline), in the relief of the signs and symptoms of Seasonal Allergic Rhinitis. Additionally, both the test and reference formulations will be tested for superiority against a placebo nasal spray.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fluticasone propionate Nasal Spray, 50 mcg/actuation; 200 mcg/day for 14 days
Drug: Fluticasone propionate
Flonase® (fluticasone propionate) Nasal Spray, 50 mcg/actuation; 200 mcg/day for 14 days
Drug: Flonase®
Saline Placebo Nasal Spray; 4 total sprays/day for 14 days
Drug: Placebo
50 mcg/actuation Nasal Spray
50 mcg/actuation Nasal Spray
Also known as: Fluticasone propionate (generic name)
Inactive Nasal Spray
Change From Baseline in Average AM/PM Reflective Total Nasal Symptom Score (rTNSS) Over Days 1 to 14.
Total Nasal Symptom Score (TNSS) is defined as the sum of the patient-rated nasal symptom severity scores for the following four allergy symptoms: Runny Nose, Nasal Congestion, Itchy Nose, and Sneezing. The severity score for each symptom will be based on a 4-point scale (0 = none, 1 = mild, 2 = moderate, and 3 = severe). The higher the score, the worse the symptoms of the 4 allergy categories are (runny nose, nasal congestions, itchy nose, and sneezing. The primary analysis for determining the therapeutic equivalence of the Test and Reference treatments will be based on each treatment's mean change from baseline for average rTNSS over the 2 week randomization treatment period. The Per-Protocol Population (PPP) will be used for the primary analysis of bioequivalence. The Modified Intent to Treat Population (mITT) will be used for Superiority Analysis.
Time frame: 2 week treatment period: Day 0-14
Change From Baseline in Average Instantaneous Total Nasal Symptom Score (iTNSS) Over Days 1 to 14.
Secondary efficacy analysis will evaluate the mean change from baseline in average iTNSS over the 2 week randomization treatment period. The Per-Protocol Population (PPP) will be used for the analysis of bioequivalence. Total Nasal Symptom Score (TNSS) is defined as the sum of the patient-rated nasal symptom severity scores for the following four allergy symptoms: Runny Nose, Nasal Congestion, Itchy Nose, and Sneezing. The severity score for each symptom will be based on a 4-point scale (0 = none, 1 = mild, 2 = moderate, and 3 = severe). The higher the score, the worse the symptoms of the 4 allergy categories are (runny nose, nasal congestions, itchy nose, and sneezing.
Time frame: 2 week treatment period: Day 0 to Day 14
Superiority to Placebo
The primary analysis for determining the superiority of each active treatment over placebo will be based on each treatment's mean change from baseline for average rTNSS over the 2 week randomization treatment period. The modified Intent-to-Treat Population (mITT) will be used for the primary analysis of superiority. Total Nasal Symptom Score (TNSS) is defined as the sum of the patient-rated nasal symptom severity scores for the following four allergy symptoms: Runny Nose, Nasal Congestion, Itchy Nose, and Sneezing. The severity score for each symptom will be based on a 4-point scale (0 = none, 1 = mild, 2 = moderate, and 3 = severe). The higher the score, the worse the symptoms of the 4 allergy categories are (runny nose, nasal congestions, itchy nose, and sneezing.
Time frame: 2 week treatment period: Day 0 to Day 14
1474 subjects with SAR were enrolled into placebo run-in for the study.
| Milestone | Investigational Test Product | Reference Listed Drug | Placebo |
|---|---|---|---|
| Started | 484 | 460 | 234 |
| Completed | 477 | 453 | 231 |
| Not completed | 7 | 7 | 3 |
| Withdrew: Adverse event | 3 | 1 | 1 |
| Withdrew: Lost to follow-up | 2 | 1 | 0 |
| Withdrew: Protocol violation | 2 | 5 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
Total Nasal Symptom Score (TNSS) is defined as the sum of the patient-rated nasal symptom severity scores for the following four allergy symptoms: Runny Nose, Nasal Congestion, Itchy Nose, and Sneezing. The severity score for each symptom will be based on a 4-point scale (0 = none, 1 = mild, 2 = moderate, and 3 = severe). The higher the score, the worse the symptoms of the 4 allergy categories are (runny nose, nasal congestions, itchy nose, and sneezing. The primary analysis for determining the therapeutic equivalence of the Test and Reference treatments will be based on each treatment's mean change from baseline for average rTNSS over the 2 week randomization treatment period. The Per-Protocol Population (PPP) will be used for the primary analysis of bioequivalence. The Modified Intent to Treat Population (mITT) will be used for Superiority Analysis.
| score on a scale | Investigational Test Product | Reference Listed Drug | Placebo |
|---|---|---|---|
| Change From Baseline in Average AM/PM Reflective Total Nasal Symptom Score (rTNSS) Over Days 1 to 14. | -1.77 ± 0.11 | -1.57 ± 0.10 | -1.26 ± 0.15 |
Secondary efficacy analysis will evaluate the mean change from baseline in average iTNSS over the 2 week randomization treatment period. The Per-Protocol Population (PPP) will be used for the analysis of bioequivalence. Total Nasal Symptom Score (TNSS) is defined as the sum of the patient-rated nasal symptom severity scores for the following four allergy symptoms: Runny Nose, Nasal Congestion, Itchy Nose, and Sneezing. The severity score for each symptom will be based on a 4-point scale (0 = none, 1 = mild, 2 = moderate, and 3 = severe). The higher the score, the worse the symptoms of the 4 allergy categories are (runny nose, nasal congestions, itchy nose, and sneezing.
| score on a scale | Investigational Test Product | Reference Listed Drug | Placebo |
|---|---|---|---|
| Change From Baseline in Average Instantaneous Total Nasal Symptom Score (iTNSS) Over Days 1 to 14. | -1.70 ± 0.11 | -1.53 ± 0.11 | -1.15 ± 0.15 |
The primary analysis for determining the superiority of each active treatment over placebo will be based on each treatment's mean change from baseline for average rTNSS over the 2 week randomization treatment period. The modified Intent-to-Treat Population (mITT) will be used for the primary analysis of superiority. Total Nasal Symptom Score (TNSS) is defined as the sum of the patient-rated nasal symptom severity scores for the following four allergy symptoms: Runny Nose, Nasal Congestion, Itchy Nose, and Sneezing. The severity score for each symptom will be based on a 4-point scale (0 = none, 1 = mild, 2 = moderate, and 3 = severe). The higher the score, the worse the symptoms of the 4 allergy categories are (runny nose, nasal congestions, itchy nose, and sneezing.
| score on a scale | Investigational Test Product | Reference Listed Drug | Placebo |
|---|---|---|---|
| Superiority to Placebo | -1.77 ± 0.11 | -1.57 ± 0.10 | -1.26 ± 0.15 |
Collected over Adverse Events were collected from the time of ICF signature through the end of the study. Total duration 4-6 weeks. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Investigational Test Product | 0/484 (0%) | 2/484 (0.4%) | 0/484 (0%) |
| Reference Listed Drug | 0/460 (0%) | 0/460 (0%) | 0/460 (0%) |
| Placebo | 0/234 (0%) | 0/234 (0%) | 0/234 (0%) |
| Event | Investigational Test Product | Reference Listed Drug | Placebo |
|---|---|---|---|
| ConcussionInjury, poisoning and procedural complications | 1/484 | 0/460 | 0/234 |
| Rib FractureInjury, poisoning and procedural complications | 1/484 | 0/460 | 0/234 |
| Conversion disorderPsychiatric disorders | 1/484 | 0/460 | 0/234 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 1/484 | 0/460 | 0/234 |
Safety Population Randomized.
| Age, Continuous(years) | Investigational Test Product | Reference Listed Drug | Placebo | Total |
|---|---|---|---|---|
| Mean | 39.3 (12 to 80) | 39.4 (12 to 76) | 39.1 (12 to 77) | 39.3 (12 to 80) |
| Sex: Female, Male(Participants) | Investigational Test Product | Reference Listed Drug | Placebo | Total |
|---|---|---|---|---|
| Female | 292 | 274 | 154 | 720 |
| Male | 192 | 186 | 80 | 458 |
| Race (NIH/OMB)(Participants) | Investigational Test Product | Reference Listed Drug | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 | 2 |
| Asian | 9 | 10 | 6 | 25 |
| Native Hawaiian or Other Pacific Islander | 2 | 1 | 1 | 4 |
| Black or African American | 114 | 108 | 64 | 286 |
| White | 357 | 339 | 160 | 856 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 2 | 2 | 5 |
Ran from Mar 2014 to primary completion in Jul 2014, 4 months.
Results were first posted in Jun 2023, 8 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluticasone
Rhinitis, Allergic, Seasonal →